


FOOTNOTES



1

Fig. 1a




Fig. 1b

3/25




Fig. 1c




Fig. 1d




Fig. 1e


[illegible]

Fig. 1f

7/25




Fig. 1g

8/25




Fig. 2a

9/25




Fig. 2b

10/25




Fig. 3

11/25




Fig. 4a

12/25




Fig. 4b




Fig. 4c




Fig. 5a




Fig. 5b

16/25



Mevastatin



Simvastatin

Fig. 5c

095047.001-095060

Ragi cells

IFN- γ /Simva
L-Mevalonate

IFN- γ /Simva

IFN- γ /Atorva

IFN- γ /Lova

IFN- γ /Prava

IFN- γ

Control




Fig. 6




Fig. 7




Fig. 8




Fig. 9a

Statin treatment



CD40L staining

Fig. 9b





Fig. 9c

23/25

Day 10 after Tx



Day 14 after Tx






Fig. 10

24/25

Day 6 after onset of arthritis



Day 12 after onset of arthritis



Control Low dose High dose
 Statin

Fig. 11

| | ³ H] Thymidine incorporation [cpm] | IFN- γ production [pg/ml] |
|-----------|--|-------------------------------------|
| Control | 13,830 (\pm 7,078) | 60,112 (\pm 13,532) |
| Low dose | 6,508 (\pm 6,499) * | 36,368 (\pm 8,005) * |
| High dose | 5,221 (\pm 7,632) * | 29,805 (\pm 8,114) * |

Fig. 12